Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316173 · ClinicalTrials.gov registry record · Phase 2
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00316173 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 77 participants.
The verdict
NCT00316173, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.
Interventions
- DRUG topotecan
- DRUG CARBOPLATIN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316173
The ClinicalTrials.gov registry entry for NCT00316173 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which topotecan is the first listed.
NCT00316173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316173 about?
NCT00316173 is a clinical study titled "Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer". This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.
What is the current status of trial NCT00316173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2005-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00316173?
The interventions under investigation include: topotecan (DRUG), CARBOPLATIN (DRUG).
Who is sponsoring clinical trial NCT00316173?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.